<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734587</url>
  </required_header>
  <id_info>
    <org_study_id>SBI IN CTO INTERVENTION</org_study_id>
    <nct_id>NCT04734587</nct_id>
  </id_info>
  <brief_title>Evaluation of Brain Damage Due to Coronary Angioplasty in Percutaneous Intervention Patients</brief_title>
  <official_title>Assessment of Silent Brain Injury in Chronic Total Occlusion Patients With Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ondokuzmayıs University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ondokuzmayıs University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the formation mechanism and patient-related factors of silent cerebral&#xD;
      infarcts, whose importance has become increasingly recognized in patients undergoing&#xD;
      percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was produced from the assistant's thesis and was previously accepted as a poster&#xD;
      at EuroPCR 2020. We recently completed the full-length article.&#xD;
&#xD;
      This thesis study was supported by Ondokuzmayis University.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Actual">March 25, 2020</completion_date>
  <primary_completion_date type="Actual">March 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Neuron-specific Enolase (NSE) measurement</measure>
    <time_frame>NSE blood levels were measured 1-2 hours before the procedure.</time_frame>
    <description>Baseline NSE measurement to exclude non-PCI dependent brain injury. Elevation of &gt;20 ng/ml was considered as silent brain injury. Patients with basal nse elevation were considered as SBI and excluded from the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Silent Brain Injury diagnosis</measure>
    <time_frame>12-18 hours after percutaneous coronary intervention</time_frame>
    <description>NSE blood levels were measured 12-18 hours after the procedure. Elevation of &gt;20 ng/ml was considered as SBI.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Silent Stroke</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Total Occlusion</arm_group_label>
    <description>Chronic total occlusion patients undergoing percutaneous coronary intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Chronic Total Occlusion</arm_group_label>
    <description>Non-Chronic total occlusion patients undergoing percutaneous coronary intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood serum Neuron-specific Enolase measurement</intervention_name>
    <description>The Silent Brain Injury ratio was compared by measuring the Neuron-specific enzyme level with venous blood sampling from both patient groups before and after percutaneous coronary intervention.</description>
    <arm_group_label>Chronic Total Occlusion</arm_group_label>
    <arm_group_label>Non-Chronic Total Occlusion</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were planned to have revascularization due to CTO in at least one coronary&#xD;
        artery (CTO Group) and patients who were scheduled for single-vessel elective coronary&#xD;
        intervention other than CTO were defined as Non-CTO (control group).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CTO and Non-CTO patients undergoing percutaneous coronary intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  baseline NSE elevation&#xD;
&#xD;
          -  acute coronary syndromes or cardiac surgery within 4 weeks&#xD;
&#xD;
          -  patients with a cerebrovascular accident&#xD;
&#xD;
          -  intracranial hemorrhage&#xD;
&#xD;
          -  and head trauma&#xD;
&#xD;
          -  central nervous system tumor&#xD;
&#xD;
          -  degenerative central nervous system disorders and neuroendocrine tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammet Uyanık, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ondokuzmayıs University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ondokuzmayis University</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ondokuzmayıs University</investigator_affiliation>
    <investigator_full_name>Muhammet Uyanik</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>silent brain injury</keyword>
  <keyword>chronic total occlusion</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>Neuron specific enolase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

